DOP2019000207A - Composición líquida que contiene pradofloxacina - Google Patents

Composición líquida que contiene pradofloxacina

Info

Publication number
DOP2019000207A
DOP2019000207A DO2019000207A DO2019000207A DOP2019000207A DO P2019000207 A DOP2019000207 A DO P2019000207A DO 2019000207 A DO2019000207 A DO 2019000207A DO 2019000207 A DO2019000207 A DO 2019000207A DO P2019000207 A DOP2019000207 A DO P2019000207A
Authority
DO
Dominican Republic
Prior art keywords
composition containing
liquid composition
pradofloxacin
containing pradofloxacin
thioglycerol
Prior art date
Application number
DO2019000207A
Other languages
English (en)
Inventor
Heep Iris
Billian Patrick
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of DOP2019000207A publication Critical patent/DOP2019000207A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas en forma líquida que comprende pradofloxacina en una solución acuosa y ácido cítrico o tioglicerol como antioxidantes.
DO2019000207A 2017-02-13 2019-08-13 Composición líquida que contiene pradofloxacina DOP2019000207A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17155885 2017-02-13

Publications (1)

Publication Number Publication Date
DOP2019000207A true DOP2019000207A (es) 2019-08-30

Family

ID=58043920

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000207A DOP2019000207A (es) 2017-02-13 2019-08-13 Composición líquida que contiene pradofloxacina

Country Status (24)

Country Link
US (2) US10780168B2 (es)
EP (1) EP3579820B1 (es)
JP (1) JP7257322B2 (es)
KR (1) KR102504435B1 (es)
CN (1) CN110248643B (es)
AR (1) AR111032A1 (es)
AU (1) AU2018217931B2 (es)
BR (1) BR112019016543A2 (es)
CA (1) CA3053211A1 (es)
CL (1) CL2019002283A1 (es)
CO (1) CO2019008677A2 (es)
CR (1) CR20190370A (es)
DO (1) DOP2019000207A (es)
ES (1) ES2886088T3 (es)
IL (1) IL268329B (es)
MX (1) MX2019009572A (es)
PE (1) PE20191462A1 (es)
PH (1) PH12019501946A1 (es)
RU (1) RU2019128568A (es)
SG (1) SG11201907073TA (es)
TW (1) TWI778017B (es)
UA (1) UA124124C2 (es)
UY (1) UY37603A (es)
WO (1) WO2018146194A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501160A (en) * 1995-12-21 2001-10-26 Pfizer Subcutaneously injectable quinolone formulations with zinc or magnesium compounds and a co-solvent
US6323213B1 (en) 1996-02-23 2001-11-27 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
DE19854356A1 (de) 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854357A1 (de) 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908448A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure
JP4373649B2 (ja) * 2002-08-01 2009-11-25 ロート製薬株式会社 経口用液剤
DE102004015981A1 (de) 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
JP4964587B2 (ja) * 2004-05-11 2012-07-04 第一三共株式会社 Ｂｈ４反応性高フェニルアラニン血症治療剤
AU2012202013A1 (en) 2004-12-09 2012-05-03 Bayer Intellectual Property Gmbh Medicament for hygienic application inside the ear
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
JP4921750B2 (ja) * 2005-09-14 2012-04-25 株式会社日本点眼薬研究所 ピレノキシンまたは薬理学的に許容される塩を含有する懸濁性医薬組成物
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
JP5624281B2 (ja) * 2009-04-21 2014-11-12 東亜薬品株式会社 光安定性に優れたキノロン系抗菌薬含有液体製剤
CN103830240B (zh) * 2012-11-27 2016-07-06 洛阳惠中兽药有限公司 一种氟喹诺酮药物组合物
CN102988286A (zh) * 2012-12-13 2013-03-27 江苏恒丰强生物技术有限公司 一种恩诺沙星注射液
DK3782617T3 (da) * 2014-09-04 2024-03-04 Lobsor Pharmaceuticals Ab Farmaceutiske gelsammensætninger omfattende levodopa, carbidopa og entacapon
AR105319A1 (es) * 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico

Also Published As

Publication number Publication date
ES2886088T3 (es) 2021-12-16
UY37603A (es) 2018-08-31
IL268329A (en) 2019-09-26
TWI778017B (zh) 2022-09-21
CL2019002283A1 (es) 2020-01-17
RU2019128568A (ru) 2021-03-15
AU2018217931B2 (en) 2023-04-13
AU2018217931A1 (en) 2019-08-22
US20200376126A1 (en) 2020-12-03
MX2019009572A (es) 2019-10-02
JP7257322B2 (ja) 2023-04-13
PH12019501946A1 (en) 2020-06-01
US11617792B2 (en) 2023-04-04
CN110248643A (zh) 2019-09-17
US20200030449A1 (en) 2020-01-30
EP3579820A1 (en) 2019-12-18
CR20190370A (es) 2019-10-21
PE20191462A1 (es) 2019-10-16
US10780168B2 (en) 2020-09-22
EP3579820B1 (en) 2021-04-28
AR111032A1 (es) 2019-05-29
KR20190112733A (ko) 2019-10-07
CO2019008677A2 (es) 2019-08-30
UA124124C2 (uk) 2021-07-21
SG11201907073TA (en) 2019-08-27
NZ755854A (en) 2023-11-24
CA3053211A1 (en) 2018-08-16
JP2020507570A (ja) 2020-03-12
WO2018146194A1 (en) 2018-08-16
KR102504435B1 (ko) 2023-02-27
IL268329B (en) 2021-08-31
TW201831184A (zh) 2018-09-01
CN110248643B (zh) 2023-11-24
BR112019016543A2 (pt) 2020-03-31
RU2019128568A3 (es) 2021-03-15

Similar Documents

Publication Publication Date Title
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2016001547A1 (es) Composiciones para el cuidado oral
MA39727A (fr) Compositions antimicrobiennes pour végétaux
MY179756A (en) Stabilized efinaconazole formulations
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
AR098168A1 (es) Formulación estable de insulina glulisina
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2016011938A (es) Composicion farmaceutica liquida.
CO2017007316A2 (es) Formulación farmacéutica
ECSP15010550A (es) Preparación farmacéutica sólida que contiene levotiroxina
CO2018010937A2 (es) Sistemas de formulación para glicolípidos antimicrobianos
EA201990093A1 (ru) Двухкомпонентная композиция
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
GEP20237486B (en) Formulations of copanlisib
MA41171A (fr) Acides pyridyl-cycloalkyl-carboxylic substitués, compositions les contenant et leurs utilisations médicales
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
UY35690A (es) Composiciones farmacéuticas de ranolazina y dronedarona
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.
CZ2014676A3 (cs) Aplikační směs pro zvýšení účinnosti antiseptik a/nebo dezinficiens, aplikační prostředek obsahující aplikační směs, a použití této směsi
DOP2019000207A (es) Composición líquida que contiene pradofloxacina
IN2015DN04074A (es)
TR201819130T4 (tr) Sulu Formülasyonlar, Bunların Üretimi Ve Kullanımı